Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2CNS 1

Conditions

Breast Neoplasms 2Neoplasm Metastasis 1

Interventions

Trastuzumab 692Paclitaxel 678Cyclophosphamide 634Docetaxel 553Capecitabine 467Letrozole 407Carboplatin 392Fulvestrant 377Doxorubicin 330Tamoxifen 288pembrolizumab 270Anastrozole 252Epirubicin 249exemestane 238pertuzumab 226Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × gancotamab × Breast × Clear all
NCT01304797 2017-01-06

Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

Merrimack Pharmaceuticals

Phase 1 Unknown
75 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02213744 2017-01-06

HERMIONE

Merrimack Pharmaceuticals

Phase 2/3 Terminated
113 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡